Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071637 | 0.79 | ALDH1A1 (0.39) | KDM4EALDH1A1HSD17B10HTTADORA2A | |
| SCHEMBL6071879 | 0.75 | KDM4E (0.39) | KDM4EALDH1A1HSD17B10HTTADORA2A | |
| SCHEMBL6071420 | 0.74 | KDM4E (0.39) | KDM4EALDH1A1HSD17B10HTTADORA2A | |
| SCHEMBL6071685 | 0.71 | KDM4E (0.39) | KDM4EALDH1A1HSD17B10HTTADORA2A | |
| SCHEMBL16655881 | 0.71 | NISCH (0.48) | IDO1ADRA2AADRA2B | |
| SCHEMBL6251698 | 0.69 | KDM4E (0.67) | KDM4EALDH1A1GLAADORA2AHPGD | |
| SCHEMBL6257122 | 0.69 | ADORA1 (0.54) | IDO1KDM4EALDH1A1GLAADORA2A | |
| SCHEMBL8002709 | 0.69 | IDO1 (0.36) | IDO1KDM4EALDH1A1HSD17B10HTT | |
| SCHEMBL6250856 | 0.68 | IDO1 (0.56) | IDO1KDM4EALDH1A1GLAADORA2A | |
| SCHEMBL26260004 | 0.68 | IDO1 (0.58) | IDO1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | IDO1 1839/4885KDM4E 1032/4885ALDH1A1 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.